drugset / Trial / NCT03784599
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Phase 2
Terminated
28 enrolled
The Netherlands Cancer Institute
AstraZeneca · collabRoche Pharma AG · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm open-label multi-center phase II study, investigating disease control rate after 3 months of treatment with trastuzumab-emtansine/osimertinib combination therapy in patients with advanced EGFR mutation positive non-small cell lung cancer (NSCLC) with HER2 bypass track resistance.
Timeline
- Start
- 2018-12-18
- Primary completion
- 2021-05-17
- Completion
- 2021-05-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Osimertinib | Small molecule | 80 mg | Oral |
| Subject | Trastuzumab emtansine | Other / unclassified | 3 mg/kg | — |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | — |